Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

News provided by

Mar 19, 2024, 16:15 ET

CORAL GABLES, Fla., March 19, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the fourth quarter and full year ended December 31, 2023. The Company will host a conference call today, Tuesday, March 19, at 4:30 PM Eastern Time/1:30 PM Pacific Time.

"We continue to make solid progress in advancing our ongoing Phase 3 program for REL-1017 as an adjunctive treatment for major depressive disorder (MDD)," said Sergio Traversa, Relmada's Chief Executive Officer. "Enrollment in the ongoing Reliance II (study 302) is steadily proceeding, and we expect top line data in the second half of 2024. In our second Phase 3 trial for REL-1017, Relight (study 304), we began dosing patients during the third quarter of last year, and we plan to complete enrollment in this study by year-end 2024."

"In our promising low dose metabolic psilocybin program (REL-P11) , which showed significant therapeutic potential on multiple parameters in pre-clinical rodent studies, we intend to initiate a single-ascending dose Phase 1 trial in obese patients in the first half of this year to define the pharmacokinetic, safety, and tolerability profile of our modified-release psilocybin formulation in this population," continued Mr. Traversa. "This will be followed by a Phase 2a trial to establish clinical proof-of-concept."

Recent Corporate Highlights

Presented new preclinical data on its novel psilocybin at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2023^® 2023 in November 2023
Appointed Dr. Andrew Cutler as Senior Clinical Development Advisor. Dr. Cutler has been conducting clinical research since 1993 and has been a Principal Investigator on over 400 clinical trials in a variety of CNS and medical indications, focusing on MDD, Bipolar Disorder, ADHD and Schizophrenia in children, adolescents and adults.

Upcoming Anticipated Milestones

Complete enrollment in ongoing RELIANCE II, which is planned to enroll approximately 300 patients, with top-line data in the second half of 2024.
Complete enrollment in the Relight study (study 304), which is planned to enroll approximately 300 patients, by year-end 2024.
Commence a Phase 1 trial in obese patients in the first half of 2024 to define the pharmacokinetic, safety and tolerability profile of the Company's modified-release psilocybin formulation (REL-P11), followed by a Phase 2a trial to establish clinical proof-of-concept with data expected in the first half of 2025.

Fourth Quarter 2023 Financial Results

Research and development expense for the three months ended December 31, 2023, totaled $14.8 million, compared to $26.9 million for the three months ended December 31, 2022. The decrease was primarily driven by a decrease in study costs associated with the completion of two Phase 3 trials and the long-term, open-label, safety trial (Study 310).
General and administrative expense for the three months ended December 31, 2023, totaled $12.1 million compared to $11.8 million for the three months ended December 31, 2022, an increase of approximately $0.3 million. The increase was primarily driven by an increase in compensation expense due to higher employee-related costs.
Net cash used in operating activities for the three months ended December 31, 2023, totaled $10.3 million compared to $35.9 million for the three months ended December 31, 2022.
The net loss for the three months ended December 31, 2023, was $25.2 million, or $0.84 per basic and diluted share, compared with a net loss of $37.9 million, or $1.28 per basic and diluted share, for the three months ended December 31, 2022.

Full-Year 2023 Financial Results

Research and development expense for the year ended December 31, 2023, totaled $54.8 million, compared to $113.3 million for the year ended December 31, 2022. The decrease was primarily driven by a decrease in study costs associated with the completion of two Phase 3 trials and the long-term, open-label, safety trial (Study 310).
General and administrative expense for the year ended December 31, 2023, totaled $48.9 million, compared to $47.9 million for the year ended December 31, 2022. The increase was primarily driven by an increase in compensation.
Net cash used in operating activities for the year ended December 31, 2023, totaled $51.7 million, compared to $103.8 million for the year ended December 31, 2022.
Net loss for the year ended December 31, 2023 and 2022 was $98.8 million and $157.0 million, respectively. The Company had a net loss of $3.28 and $5.30 per basic and diluted share for the year ended December 31, 2023 and 2022, respectively.
As of December 31, 2023, the Company had cash, cash equivalents, and short-term investments of approximately $96.3 million, compared to cash, cash equivalents, and short-term investments of approximately $148.3 million at December 31, 2022.

Conference Call and Webcast Details

*Tuesday, March 19^th @ 4:30pm ET*
Toll Free:	888-886-7786
International:	416-764-8658
Conference ID:	35626110
Webcast:	Click Here

About REL-1017

REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the adjunctive treatment of major depressive disorder (MDD). Relmada's ongoing clinical research program is designed to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment. The development program for REL-1017 as an adjunctive treatment for MDD includes two Phase 3 randomized, double-blind, placebo-controlled studies, Reliance II (Study 302) and Relight (Study 304). Reliance II and Relight have the same key study design parameters.

About REL-P11

Relmada acquired the development and commercial rights to a novel psilocybin and derivatives program in July of 2021. Psilocybin has neuroplastogen™ effects that have the potential to ameliorate neurodegenerative conditions. The pleiotropic metabolic effects of low-dose psilocybin were discovered while studying its neuroplastogen™ potential in a rodent model deficient in neurogenesis – obese rats maintained on a high fructose, high fat diet (HFHFD), and were then replicated in mice.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com.

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential failure of clinical trial results to demonstrate statistically and/or clinically significant evidence of efficacy and/or safety, failure of top-line results to accurately reflect the complete results of the trial, failure of the 310 open-label study to accurately reflect the results of the ongoing 302 and 304 blinded, randomized and controlled studies, failure to obtain regulatory approval of REL-1017 for the treatment of major depressive disorder, failure of the planned psilocybin Phase 1 and Phase 2a trials to be successfully initiated and carried out, and the other risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.

Investor Contact:
Tim McCarthy
LifeSci Advisors
[email protected]

Media Inquiries:
Corporate Communications
[email protected]

Relmada Therapeutics, Inc. Consolidated Balance Sheets (Unaudited)

	As of		As of
	December 31,		December 31,
	2023		2022
Assets
Current assets:
Cash and cash equivalents	$	4,091,568	$	5,395,905
Short-term investments		92,232,292		142,926,781
Other receivables		-		512,432
Prepaid expenses		1,185,057		4,035,186
Total current assets		97,508,917		152,870,304
Other assets		43,125		34,875
Total assets	$	97,552,042	$	152,905,179

Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$	3,506,009	$	5,261,936
Accrued expenses		8,688,791		7,206,941
Total current liabilities		12,194,800		12,468,877
Total liabilities		12,194,800		12,468,877

Commitments and Contingencies (Note 7)

Stockholders' Equity:
Preferred stock, $0.001 par value, 200,000,000 shares authorized, none issued and outstanding		-		-
Class A convertible preferred stock, $0.001 par value, 3,500,000 shares authorized, none issued and outstanding		-		-
Common stock, $0.001 par value, 150,000,000 shares authorized, 30,099,203 and 30,099,203 shares issued and outstanding, respectively		30,099		30,099
Additional paid-in capital		646,229,824		602,517,138
Accumulated deficit		(560,902,681)		(462,110,935)
Total stockholders' equity		85,357,242		140,436,302
Total liabilities and stockholders' equity	$	97,552,042	$	152,905,179

Relmada Therapeutics, Inc. Consolidated Statements of Operations (Unaudited)

	2023		2022
Operating expenses:
Research and development	$	54,807,348	$	113,322,999
General and administrative		48,894,945		47,926,077
Total operating expenses		103,702,293		161,249,076

Loss from operations		(103,702,293)		(161,249,076)

Other income (expenses):
Gain on settlement of fees		-		6,351,606
Interest/investment income, net		5,151,704		2,659,424
Realized loss on short-term investments		(4,064,391)		(585,522)
Unrealized gain (loss) on short-term investments		3,823,234		(4,220,255)
Total other income (expenses), net		4,910,547		4,205,253

Net loss	$	(98,791,746)	$	(157,043,823)

Net loss per common share – basic and diluted	$	(3.28)	$	(5.30)

Weighted average number of common shares outstanding – basic and diluted		30,099,203		29,628,664

Relmada Therapeutics, Inc. Consolidated Statements of Changes in Stockholders' Equity For the Years Ended December 31, 2023 and 2022

	Common Stock				Additional Paid-in		Accumulated
	Shares		Par Value		Capital		Deficit		Total
Balance – December 31, 2021		27,740,147	$	27,740	$	513,304,258	$	(305,067,112)	$	208,264,886
Stock-based compensation expense		-		-		44,194,765		-		44,194,765
ATM offering, net		2,094,243		2,094		42,726,505		-		42,728,599
Share exchange – Prefunded warrants, net of fees		(1,452,016)		(1,452)		(48,548)		-		(50,000)
Net exercise – Prefunded warrants		1,451,795		1,452		(1,452)		-		-
Warrants exercised		181,336		181		1,264,342		-		1,264,523
Options exercised		83,698		84		703,636		-		703,720
Short swing profit, net		-		-		373,632		-		373,632
Net loss		-		-		-		(157,043,823)		(157,043,823)
Balance – December 31, 2022		30,099,203		30,099		602,517,138		(462,110,935)		140,436,302
Stock-based compensation expense		-		-		43,811,149		-		43,811,149
ATM fees		-		-		(98,463)		-		(98,463)
Net loss		-		-		-		(98,791,746)		(98,791,746)
Balance – December 31, 2023		30,099,203	$	30,099	$	646,229,824	$	(560,902,681)	$	85,357,242

Relmada Therapeutics, Inc. Consolidated Statements of Cash Flows (Unaudited)

	2023		2022
Cash flows from operating activities
Net loss	$	(98,791,746)	$	(157,043,823)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		43,811,149		44,194,765
Gain on settlement		-		(6,351,606)
Realized loss on short-term investments		4,064,391		585,522
Unrealized (gain) loss on short-term investments		(3,823,234)		4,220,255
Change in operating assets and liabilities:
Lease payment receivable		-		86,377
Other receivable		512,432		(512,432)
Prepaid expenses and other assets		2,841,879		7,259,767
Accounts payable		(1,755,927)		421,040
Accrued expenses		1,481,850		3,338,518
Net cash used in operating activities		(51,659,206)		(103,801,617)

Cash flows from investing activities
Purchase of short-term investments		(90,463,532)		(47,293,763)
Sale of short-term investments		140,916,864		67,027,372
Net cash provided by investing activities		50,453,332		19,733,609

Cash flows from financing activities
Payment of ATM fees		(98,463)		-
Payment of fees for warrants issued for common stock		-		(50,000)
Proceeds from issuance of common stock		-		42,728,599
Proceeds from options exercised for common stock		-		703,720
Proceeds from warrants exercised for common stock		-		1,264,523
Proceeds from short swing profit, net		-		373,632
Net cash (used in) provided by financing activities		(98,463)		45,020,474

Net decrease in cash and cash equivalents		(1,304,337)		(39,047,534)
Cash and cash equivalents at beginning of the period		5,395,905		44,443,439
Cash and cash equivalents at end of the period	$	4,091,568	$	5,395,905